The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1255-1258

  Hirth, JoAnn ^a   Watkins, Paul B ^a   Strawderman, Myla ^a   Schott, Anne ^a   Bruno, René ^b   Baker, Laurence H ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; CYTOCHROME C OXIDASE; DOCETAXEL; ERYTHROMYCIN;

ADULT; ARTICLE; BLOOD SAMPLING; CATALYSIS; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; GENETIC VARIABILITY; HUMAN; INDIVIDUALITY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE NEOPLASMS; BREATH TESTS; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OROSOMUCOID; PACLITAXEL; SARCOMA; SOFT TISSUE NEOPLASMS; TAXOIDS;

EID: 0034047560     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Linder, M. W., Prough, R. A., and Valdes, R., Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem., 43: 254-266, 1997.
2. Kivistö, K. T., Kroemer, H. K., and Eichelbaum, M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interaction. Br. J. Clin. Pharmacol., 40: 523-530, 1995.
3. Watkins, P. B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 4: 171-184, 1994.
4. Turgeon, D. K., Leichtman, A. B., Blake, D. S., Schmouder, R. L., Lown, K. S., Annesley, T. M., and Watkins, P. B. Prediction of inter-patient variation in OG-37-325 dosing requirements by the erythromycin breath test. Transplantation (Baltimore), 57: 1736-1741, 1994.
5. Marre, F., Sanderink, G. J., de Sousa, G., Gaillard, C., Martinet, M., and Rahmani, R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res., 56: 1296-1302, 1996.
6. 14 radiolabeled Taxotere in cancer patients. Proc. Am. Assoc. Cancer Res., 34: 373, 1993.
7. Bruno, R., Vivier, N., Vergniol, J. C., DePhillips, S. L., Montay, G., and Sheiner, L. B. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J. Pharmacokinet. Biopharm., 24: 153-172, 1996.
8. Bruno, R., Hille, D., Riva, A., Vivet, N., ten Bokkel Huinnink, W. W., van Oosterom, A. T., Kaye, S. B., Verweij, J., Fossella, F. V., Valero, V., Rigas, J. R., Seidman, A. D., Chevallier, B., Fumoleau, P., Burris, H. A., Ravdin, P. M., and Sheiner, L. B. Population pharmacokinetics/pharmacodynamics of docetaxel in Phase II studies in patients with cancer. J. Clin. Oncol., 16: 187-196, 1998.
9. Kaye, S. B. Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer. Semin. Oncol., 22 (Suppl. 4): 30-33, 1995.
10. van Hoesel, Q. G., Verweij, J., Catimel, G., Clavel, M., Kerbrat, P., van Oosterom, A. T., Kerger, J., Tursz, T., van Glabbeke, M., and van Pottelsberghe, C. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann. Oncol., 5: 539-542, 1994.
11. Wagner, D. CYP3A4 and the erythromycin breath test. Clin. Pharmacol. Ther., 64: 129-130, 1998.
12. Baille, P., Bruno, R., Schellens, J. H., Webster, L. K., Millward, M., Verweij, J., and Montay, G. Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance. Clin. Cancer Res., 3: 1535-1538, 1997.
13. Vergniol, J. C., Bruno, R., Montay, G., and Frydman, A. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J. Chromatogr., 582: 273-278, 1992.
14. Beal, S. L., and Shener, L. B. (eds.), Nonlinear Mixed Effects Model Users Guides. San Francisco, CA: NONMEM Project Group, University of California at San Francisco, 1999.
15. Bruno, N., Vivier, C., Houver, G., Montay, G., and Riva, A. Lack of influence of dexamethasone premedication on docetaxel (Taxotere) pharmacokinetics. Ann. Oncol., 7 (Suppl. 1): A335, 1996.